Trials / Unknown
UnknownNCT03944980
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer
Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-Lymphocyte (PD1-T) Combined With Docetaxel in the Second-line Treatment of IIIB/IIIC/IV Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 146 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte (PD1-T) combined with docetaxel in the second-line treatment of IIIB/IIIC/IV non-small cell lung cancer. Half of participants receive PD1-T combined with docetaxel, while the other half will receive docetaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Docetaxel injection |
| BIOLOGICAL | PD1-T cells | PD1-T cells injection |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2021-06-01
- Completion
- 2022-06-01
- First posted
- 2019-05-10
- Last updated
- 2019-06-14
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03944980. Inclusion in this directory is not an endorsement.